HyTest's current majority owner, Summa Equity, has signed a definitive agreement to sell HyTest to Mindray, a leading global medical technology company. HyTest has been partnering with Mindray already for over ten years. In going forward, HyTest is committed to serving all of its customers and will continue to provide high-quality diagnostic raw materials as before.
"We are delighted to partner with Mindray as we look forward to the future in delivering the best products and service to our global customer base. With the resources available from Mindray, we can further develop our capabilities to serve our customers and fulfill their needs for best-in-class reagents for developing reliable and sensitive immunoassays on various platforms" says Juhana Rauramo, CEO of HyTest.
“HyTest, a world-renowned, top-notch supplier of upstream IVD raw materials, has established friendship and mutual trust with Mindray during more than 10 years of cooperation. Upon completion of the transaction, we expect HyTest to invest additional resources to continuous development of technologies and products as well as advance technological innovation and academic exploration. We will strive to help HyTest serve global IVD customers with products and services of more premium performance and quality. We’re determined to support HyTest to keep investing in R&D as well as strengthen and improve its key competitive edge, so as to maintain its position as a global leader in the specialty upstream IVD raw material business.”
— Hao WU, President of Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
Read the whole press release here.